1446 Results
Sort By:
Published on March 4, 2016
For all its genetic diversity, a tumor may yet display some common elements, antigens that reflect the tumor’s early mutational history. If these common elements could be identified, they could be used to target practically all of the tumor’s cells for destruction, and not just tumor cells that happen to…
Published on March 1, 2016
Researchers at the University of Miami Miller School of Medicine discovered a biomarker that puts patients at a higher risk for metastasis of uveal melanoma, a type of eye cancer. Among uveal melanomas categorized as class 1, those with high levels of the biomarker PRAME mRNA were more likely to…
Published on January 11, 2016
Thermo Fisher Scientific plans to buy Affymetrix for $1.3 billion, in a deal the buyer said will strengthen its position in bioscience research tools and genetic analysis. The deal, announced Friday after the close of financial markets, expands Thermo Fisher’s offerings with Affymetrix’s technologies, designed to enable parallel and multiplex…
Published on January 5, 2016
Virtual tumors—computer simulations that incorporate a patient’s genomic information—can help personalize cancer care. They have already been used to predict patient responses to drug treatments. In particular, virtual tumors have identified which patients are likely to respond to checkpoint inhibitors, drugs meant to prevent cancers from overriding host immune checkpoints.…
Published on November 18, 2015
Thermo Fisher Scientific said today it will partner with Novartis and Pfizer to develop and commercialize a companion diagnostic for non-small cell lung cancer (NSCLC) across multiple drug development programs. The value of the collaboration was not disclosed. The companion diagnostic will be a multimarker, universal next-generation sequencing (NGS) oncology…
Published on November 5, 2015
A collaborative team of researchers from the Translational Genomics Research Institute (TGen), Mayo Clinic, and Cancer Research UK Cambridge Institute (CRUK) have successfully shown that circulating tumor DNA (ctDNA), shed into the blood stream from cancer cells, can be used to track the progression of cancers and their response to…
Published on October 15, 2015
Researchers from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have harnessed the power of next-generation sequencing to analyze a large collection of leukemia tissue samples. Using whole exome sequencing (WES), the investigators screened genetic material from more than 500 samples of chronic lymphocytic leukemia (CLL)…
Published on October 1, 2015
Those of you who have a working knowledge of applied Latin can do a quick and easy translation and deduce that pons asinorum literally means the “bridge of donkeys.” Traditionally, it refers to the proof of the isosceles triangle theorem in Euclid’s Elements, and connotes a challenge that separates the…
Published on August 27, 2015
Conducted repeatedly, a blood test capable of profiling circulating tumor DNA can track genetic changes that occur over time, picking up signs that a treated cancer—in this case, breast cancer—is about to return. The blood test, a so-called liquid biopsy, detects mutations in DNA shed by cancer cells, and it…
Published on August 26, 2015
While the incidence of acute myeloid leukemia (AML) is still relatively rare, accounting for approximately 1% of cancer deaths in the U.S., rates of occurrence are expected to rise as the largest portion of the population continues to age. Moreover, there remains a significant level of disparity in clinical outcomes,…
Published on August 26, 2015
Sequenom agreed to a clinical research collaboration with the University of California, San Diego Moores Cancer Center. Moores will explore the utility of Sequenom's new liquid biopsy assay to profile circulating cell-free tumor DNA in blood to enable serial monitoring and assist with therapy selection in cancer patients. This technology…
Published on August 20, 2015
One of the main goals of personalized medicine is the ablity to quickly and accurately determine the genetic background of a patient and prescribe the appropriate therapy based on their mutational signature. To address this vital component of modern medicine initiatives, researchers have designed a new form of clinical trial,…
Published on May 21, 2015
Based on the most current data, approximately 14% of men will be diagnosed with prostate cancer at some point during their lifetime. If detected early, long term clinical prognosis is very good, however in many cases, prostate cancer can become metastatic and drug resistant tumor rates are on the rise. …
Published on May 4, 2015
Scientists at the University of North Carolina School of Medicine and UNC Lineberger Comprehensive Cancer Center say they have developed a technique for finding where DNA repair happens throughout all of human DNA. Their study (“Genome-wide analysis of human global and transcription-coupled excision repair of UV damage at single-nucleotide resolution”),…
Published on May 16, 2014
The use of targeted agents against key signaling kinases is transforming cancer treatment. Drugs such as Herceptin and Zelboraf have increased progression-free survival in breast cancer and melanoma respectively and are far from the only examples. However, the complexity of signaling pathway networks allows tumor cells to adapt under monotherapy…